Clinical applications of susceptibility-weighted imaging in detecting and grading intracranial gliomas: A review

Cancer Imaging

Volumn 13, Issue 2, 2013, Pages 186-195

  Mohammed, Wasif ^a   Xunning, Hong ^a   Haibin, Shi ^a   Jingzhi, Meng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HEMOSIDERIN;

ASTROCYTOMA; BLEEDING; BRAIN HEMORRHAGE; BRAIN TUMOR; CANCER DIAGNOSIS; CANCER GRADING; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; ELECTRON SPIN RESONANCE; GLIOMA; HISTOPATHOLOGY; HUMAN; MICROVASCULATURE; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; SIGNAL DETECTION; SIGNAL NOISE RATIO; SUSCEPTIBILITY WEIGHTED IMAGING; TUMOR BIOPSY; TUMOR VASCULARIZATION;

BRAIN NEOPLASMS; GLIOMA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; NEOPLASM GRADING;

EID: 84877850351     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2013.0020     Document Type: Review

References (55)

1. Emblem KE, Scheie D, Due-Tonnessen P, et al. Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes. AJNR Am J Neuroradiol 2008; 29: 1664-1670. doi:10.3174/ajnr.A1182. PMid:18583405.
2. Levis AG, Minicuci N, Ricci P, Gennaro V, Garbisa S. Mobile phones and head tumours. The discrepancies in cause-effect relationships in the epidemiological studies - how do they arise? Environ Health 2011; 10: 59. doi:10.1186/1476-069X-10-59. PMid:21679472.
3. Di Ieva A, God S, Grabner G, et al. Three-dimensional susceptibility- weighted imaging at 7 T using fractal-based quantitative analysis to grade gliomas. Neuroradiology 2013; 55: 35-40. doi:10.1007/s00234-012-1081-1. PMid:22903580.
4. Fuller GN, Scheithauer BW. The 2007 revised World Health Organization (WHO) classification of tumours of the central nervous system: newly codified entities. Brain Pathol 2007; 17: 304-307. doi:10.1111/j.1750-3639.2007.00084.x. PMid:-17598822. (Pubitemid 47000649)
5. Roberts TP, Mikulis D. Neuro MR: principles. J Magn Reson Imaging 2007; 26: 823-837. doi:10.1002/jmri.21029. PMid:- 17685415.
6. Reichenbach JR, Venkatesan R, Schillinger DJ, Kido DK, Haacke EM. Small vessels in the human brain: MR venography with deoxyhemoglobin as an intrinsic contrast agent. Radiology 1997; 204: 272-277. PMid:9205259. (Pubitemid 27281745)
7. Haacke EM, Mittal S, Wu Z, Neelavalli J, Cheng YC. Susceptibility- weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol 2009; 30: 19-30. doi:10.3174/ajnr.A1400. PMid:19039041.
8. Reichenbach JR, Barth M, Haacke EM, Klarhofer M, Kaiser WA, Moser E. High-resolution MR venography at 3.0 Tesla. J Comput Assist Tomogr 2000; 24: 949-957. doi:10.1097/00004728- 200011000-00023. PMid:11105717. (Pubitemid 32201825)
9. Higano S, Yun X, Kumabe T, et al. Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006; 241: 839-846. doi:10.1148/radiol.2413051276. PMid:17032910. (Pubitemid 46190551)
10. Lee BC, Vo KD, Kido DK, et al. MR high-resolution blood oxygenation level-dependent venography of occult (low-flow) vascular lesions. AJNR Am J Neuroradiol 1999; 20: 1239-1242. PMid:10472978. (Pubitemid 29400532)
11. Mittal S, Wu Z, Neelavalli J, Haacke EM. Susceptibility-weighted imaging: technical aspects and clinical applications, part 2. AJNR Am J Neuroradiol 2009; 30: 232-252. doi:10.3174/ajnr.A1461. PMid:19131406.
12. Robinson RJ, Bhuta S. Susceptibility-weighted imaging of the brain: current utility and potential applications. J Neuroimaging 2011; 21: e189-204. doi:10.1111/j.1552-6569.2010.00516.x. PMid:21281380.
13. Tong KA, Ashwal S, Obenaus A, Nickerson JP, Kido D, Haacke EM. Susceptibility-weighted MR imaging: a review of clinical applications in children. AJNR Am J Neuroradiol 2008; 29: 9-17. doi:10.3174/ajnr.A0786. PMid:17925363.
14. Burrell JS, Walker-Samuel S, Baker LC, et al. Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas. Int J Cancer 2012; 131: 1854-1862. doi:10.1002/ ijc.27460. PMid:22290271.
15. Lee EJ, terBrugge K, Mikulis D, et al. Diagnostic value of peritumoral minimum apparent diffusion coefficient for differentiation of glioblastoma multiforme from solitary metastatic lesions. AJR Am J Roentgenol 2011; 196: 71-76. doi:10.2214/ AJR.10.4752. PMid:21178049.
16. Lupo JM, Banerjee S, Hammond KE, et al. GRAPPA-based susceptibility- weighted imaging of normal volunteers and patients with brain tumor at 7 T. Magn Reson Imaging 2009; 27: 480-488. doi:10.1016/j.mri.2008.08.003. PMid:18823730.
17. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6. doi:10.1093/jnci/ 82.1.4. PMid:1688381. (Pubitemid 20020880)
18. de Bouard S, Guillamo JS. Angiogenesis and anti-angiogenic strategies for glioblastoma. Bull Cancer 2005; 92: 360-372. PMid:15888393.
19. Sawlani RN, Raizer J, Horowitz SW, et al. Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging-pilot study. Radiology 2010; 255: 622-628. doi:10.1148/radiol.10091341. PMid:20413772.
20. Grabner G, Nobauer I, Elandt K, et al. Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility- weighted magnetic resonance imaging at 7 T. Magn Reson Imaging 2012; 30: 139-147. doi:10.1016/ j.mri.2011.08.004. PMid:21982163.
21. Sehgal V, Delproposto Z, Haddar D, et al. Susceptibility-weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses. J Magn Reson Imaging 2006; 24: 41-51. doi:10.1002/jmri.20598. PMid:16755540.
22. Zulfiqar M, Dumrongpisutikul N, Intrapiromkul J, Yousem DM. Detection of intratumoral calcification in oligodendrogliomas by susceptibility-weighted MR imaging. AJNR Am J Neuroradiol 2012; 33: 858-864. doi:10.3174/ajnr.A2862. PMid:22268093.
23. Brasch R, Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol 2000; 34: 148-155. doi:10.1016/ S0720-048X(00)00195-9. PMid:10927157. (Pubitemid 30601689)
24. Hayashida Y, Hirai T, Morishita S, et al. Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol 2006; 27: 1419-1425. PMid:16908550. (Pubitemid 44260120)
25. Rauscher A, Sedlacik J, Barth M, Haacke EM, Reichenbach Jr. Nonnvasive assessment of vascular architecture and function during modulated blood oxygenation using susceptibility weighted magnetic resonance imaging. Magn Reson Med 2005; 54: 87-95. doi:10.1002/mrm.20520. PMid:15968657. (Pubitemid 40898400)
26. Lobel U, Sedlacik J, Sabin ND, et al. Three-dimensional susceptibility- weighted imaging and two-dimensional T2-weighted gradient- echo imaging of intratumoral hemorrhages in pediatric diffuse intrinsic pontine glioma. Neuroradiology 2010; 52: 1167-1177.
27. Di Ieva A, Matula C, Grizzi F, Grabner G, Trattnig S, Tschabitscher M. Fractal analysis of the susceptibility weighted imaging patterns in malignant brain tumors during antiangiogenic treatment: technical report on four cases serially imaged by 7 T magnetic resonance during a period of four weeks. World Neurosurg 2012; 77: 785.e11-21.
28. Lupo JM, Chuang CF, Chang SM, et al. 7-Tesla susceptibilityweighted imaging to assess the effects of radiotherapy on normal-appearing brain in patients with glioma. Int J Radiat Oncol Biol Phys 2012; 82: e493-500. doi:10.1016/ j.ijrobp.2011.05.046. PMid:22000750.
29. Sehgal V, Delproposto Z, Haacke EM, et al. Clinical applications of neuroimaging with susceptibility-weighted imaging. J Magn Reson Imaging 2005; 22: 439-450. doi:10.1002/ jmri.20404. PMid:16163700. (Pubitemid 41416402)
30. Lin W, Mukherjee P, An H, et al. Improving high-resolution MR bold venographic imaging using a T1 reducing contrast agent. J Magn Reson Imaging 1999; 10: 118-123. doi:10.1002/ (SICI)1522-2586(199908)10:25118::AID-JMRI243.0. CO;2-V. PMid:10441013. (Pubitemid 29362424)
31. Pinker K, Noebauer-Huhmann IM, Stavrou I, et al. High-field, high-resolution, susceptibility-weighted magnetic resonance imaging: improved image quality by addition of contrast agent and higher field strength in patients with brain tumors. Neuroradiology 2008; 50: 9-16. doi:10.1007/s00234- 007-0298- x. PMid:17876570.
32. Hori M, Ishigame K, Kabasawa H, et al. Precontrast and postcontrast susceptibility-weighted imaging in the assessment of intracranial brain neoplasms at 1.5 T. Jpn J Radiol 2010; 28: 299-304. doi:10.1007/s11604-010-0427- z. PMid:20512548.
33. Lou X, Ma L, Wang FL, et al. Susceptibility-weighted imaging in the diagnosis of early basal ganglia germinoma. AJNR Am J Neuroradiol 2009; 30: 1694-1699. doi:10.3174/ajnr.A1696. PMid:19581340.
34. Li C, Ai B, Li Y, Qi H, Wu L. Susceptibility-weighted imaging in grading brain astrocytomas. Eur J Radiol 2010; 75: e81-85. doi:10.1016/j.ejrad.2009.08. 003. PMid:19726149.
35. Atlas SW, Mark AS, Grossman RI, Gomori JM. Intracranial hemorrhage: gradient-echo MR imaging at 1.5 T. Comparison with spin-echo imaging and clinical applications. Radiology 1988; 168: 803-807. PMid:3406410.
36. Sadeghi N, D-Haene N, Decaestecker C, et al. Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. AJNR Am J Neuroradiol 2008; 29: 476-482. doi:10.3174/ajnr.A0851. PMid:18079184. (Pubitemid 351424060)
37. Kim HS, Jahng GH, Ryu CW, Kim SY. Added value and diagnostic performance of intratumoral susceptibility signals in the differential diagnosis of solitary enhancing brain lesions: preliminary study. AJNR Am J Neuroradiol 2009; 30: 1574-1579. doi:10.3174/ajnr.A1635. PMid:19461062.
38. Toh CH, Wei KC, Chang CN, et al. Differentiation of pyogenic brain abscesses from necrotic glioblastomas with use of susceptibility- weighted imaging. AJNR Am J Neuroradiol 2012; 33: 1534-1538. doi:10.3174/ajnr.A2986. PMid:22422181.
39. Stupp R, Pica A, Mirimanoff RO, Michielin O. [A practical guide for the management of gliomas]. Bull Cancer 2007; 94: 817-822. PMid:17878102. (Pubitemid 47605611)
40. Weber MA, Henze M, Tuttenberg J, et al. Biopsy targeting gliomas do functional imaging techniques identify similar target areas? Invest Radiol 2010; 45: 755-768. doi:10.1097/ RLI.0b013e3181ec9db0. PMid:20829706.
41. Bagley LJ, Grossman RI, Judy KD, et al. Gliomas: correlation of magnetic susceptibility artifact with histologic grade. Radiol 1997; 202: 511-516. (Pubitemid 27051751)
42. Hori M, Mori H, Aoki S, et al. Three-dimensional susceptibilityweighted imaging at 3 T using various image analysis methods in the estimation of grading intracranial gliomas. Magn Reson Imaging 2010; 28: 594-598. doi:10.1016/j.mri.2010.01.002. PMid:20233645.
43. Pinker K, Noebauer-Huhmann IM, Stavrou I, et al. High-resolution contrast-enhanced, susceptibility-weighted MR imaging at 3T in patients with brain tumors: correlation with positron-emission tomography and histopathologic findings. AJNR Am J Neuroradiol 2007; 28: 1280-1286. doi:10.3174/ajnr.A0540. PMid:17698528. (Pubitemid 47309659)
44. Park MJ, Kim HS, Jahng GH, Ryu CW, Park SM, Kim SY. Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibility- weighted imaging in patients with gliomas: comparison with MR perfusion imaging. AJNR Am J Neuroradiol 2009; 30: 1402-1408. doi:10.3174/ajnr.A1593. PMid:19369602.
45. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusionweighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999; 9: 53-60. doi:10.1002/(SICI)1522-2586(199901)9:1553:: AIDJMRI743.0. CO;2-2. PMid:10030650. (Pubitemid 29068231)
46. Castillo M, Smith JK, Kwock L, Wilber K. Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J Neuroradiol 2001; 22: 60-64. PMid:11158889. (Pubitemid 32105356)
47. Rizzo L, Crasto SG, Moruno PG, et al. Role of diffusion- and perfusion-weighted MR imaging for brain tumour characterisation. Radiol Med 2009; 114: 645-659. doi:10.1007/s11547-009- 0401-y. PMid:19430732.
48. Negendank WG, Sauter R, Brown TR, et al. Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 1996; 84: 449-458. PMid:8609557. (Pubitemid 26062870)
49. Hourani R, Brant LJ, Rizk T, Weingart JD, Barker PB, Horsk-a A. Can proton MR spectroscopic and perfusion imaging differentiate between neoplastic and nonneoplastic brain lesions in adults? AJNR Am J Neuroradiol 2008; 29: 366-372. doi:10.3174/ajnr.A0810. PMid:18055564. (Pubitemid 351287898)
50. Moller-Hartmann W, Herminghaus S, Krings T, et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002; 44: 371-381. (Pubitemid 36097186)
51. Chawla S, Wang S, Wolf RL, et al. Arterial spin-labeling and MR spectroscopy in the differentiation of gliomas. AJNR Am J Neuroradiol 2007; 28: 1683-1689. doi:10.3174/ajnr.A0673. PMid:17893221. (Pubitemid 47598140)
52. Kim JH, Chang KH, Na DG, et al. 3T 1H-MR spectroscopy in grading of cerebral gliomas: comparison of short and intermediate echo time sequence. AJNR Am J Neuroradiol 2006; 27: 1412-1418. PMid:16908549. (Pubitemid 44260119)
53. Fayed N, D-avila J, Medrano J, Olmos S. Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI. Eur J Radiol 2008; 67: 427-433. doi:10.1016/j.ejrad.2008.02.039. PMid:18442889.
54. Hu LS, Eschbacher JM, Dueck AC, et al. Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma. AJNR Am J Neuroradiol 2012; 33: 69-76. doi:10.3174/ajnr.A2743. PMid:22095961.
55. Hu CH, Fang XM, Hu XY, Cui L. Analysis of the mismatched manifestation between rCBF and rCBV maps in cerebral astrocytomas. Clin Imaging 2009; 33: 417-423. doi:10.1016/ j.clinimag.2009.01.014. PMid:19857800.